Test drug ISB 2001 in multiple myeloma patients who relapsed
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed multiple myeloma that has measurable abnormal protein (in blood and/or urine or related lab results).
- Your health and daily functioning are fairly good (ECOG score 2 or less).
- Your blood counts and organ functions are adequate (bone marrow, liver, kidneys, and heart).
- You do not have active cancer in the brain or spinal cord (central nervous system).
- You do not have a serious or uncontrolled infection needing antibiotics right before starting.
- You are not pregnant or breastfeeding during screening and on the start day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
This study tests an experimental drug called LBL-034 for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.